EUSA Pharma, rare disease and oncology biopharma firm, recently decided to add members to their senior leadership team by adding Carsten Thiel as the President of the Europe Division.
The decision came as the company has spent the past couple of years building a business that has been strong enough that they feel its the time to expand their commercialization throughout Europe. Additionally, they hired Dr. Darrel P. Cohen as the Head of Clinical Development at the same time, meaning that he’ll be overseeing projects and research on potential new products years before they even launch.
At EUSA Pharma, Dr. Carsten Thiel has a unique role. Expanding a company through commercial ventures isn’t the easiest job to take, but he was chosen based on his past. All together, Thiel has been working in the commercial business for 27 years, working at different companies such as Alexion, where he helped lead to expanding their business in their EMEA, Asia Pacific, and Australasia regions of the world.
Additionally, he worked at Amgen where he first leads the European oncology franchise of the company, later moving on to becoming the Head of Europe. The final role he took before moving on to EUSA Pharma was when he lead Abeona Therapeutics, a gene therapy specialist company, as its CEO. In the statement Thiel gave when joining EUSA Pharma, he stated that one of the reasons he decided to join the company was his ability to view the large portfolio EUSA Pharma has managed to build in the short time they have been active as a business.
To know more click: here.